Compare AR & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AR | KRYS |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 9.6B |
| IPO Year | 2013 | 2017 |
| Metric | AR | KRYS |
|---|---|---|
| Price | $37.22 | $328.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 11 |
| Target Price | $47.13 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 4.5M | 597.5K |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1027.78 | 128.00 |
| EPS | 2.62 | ★ 3.62 |
| Revenue | ★ $5,275,823,000.00 | $389,130,000.00 |
| Revenue This Year | $29.74 | $38.74 |
| Revenue Next Year | $5.07 | $32.53 |
| P/E Ratio | ★ $14.14 | $90.96 |
| Revenue Growth | 21.97 | ★ 33.94 |
| 52 Week Low | $29.10 | $142.51 |
| 52 Week High | $45.75 | $382.54 |
| Indicator | AR | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 60.96 | 46.41 |
| Support Level | $32.82 | $246.17 |
| Resistance Level | $37.80 | $377.89 |
| Average True Range (ATR) | 1.06 | 14.85 |
| MACD | 0.24 | -2.22 |
| Stochastic Oscillator | 96.10 | 47.90 |
Antero Resources is an exploration and production firm whose operations represent a pure play in the Marcellus Shale, located in northern West Virginia. The company started in 2002 as an E&P focused on the Barnett Shale (Fort Worth, Texas). Antero redefined itself in Appalachia's Marcellus Shale in 2005. In 2012, shortly before Antero's 2013 IPO, Antero Midstream Partners was formed to handle the company's rapidly growing gas volumes. In 2026, the firm narrowed its focus further by selling its Ohio Utica assets and using the proceeds to acquire additional Marcellus acreage from HG Energy. Just over half of its production and earning power is tied to natural gas, with the remainder mostly NGLs, where it holds a leading position, and some crude oil.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.